Company intelligence / Profile preview

CicloMulsion

Heidelberg, Germany

Ownership: Private
Development stage: Other

Overview

CicloMulsion was a biopharmaceutical company focused on developing a lipid emulsion formulation of cyclosporine for the prevention of reperfusion injury in patients undergoing treatment for myocardial infarction. The company's lead candidate, also named CicloMulsion, was designed to inhibit cyclophilin D, a key mediator of mitochondrial permeability transition pore opening during ischemia-reperfusion. Despite reaching Phase 3 clinical trials (the CIRCUS study), the program failed to meet its primary endpoints, leading to the cessation of development for that specific indication. The company was acquired by NeuroVive Pharmaceutical (now Abliva) to consolidate their mitochondrial medicine portfolio.

Therapeutic areas: Cardiovascular
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on CicloMulsion.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CicloMulsion.

Explore the full profile